PORTFOLIO: BLACKSTONE MEDICAL
Blackstone was in a crowded pack: some might cash out by selling off technology, others simply fail against a handful of billion-dollar players. The insight that surgeons believed FDA regulations ensured product parity could be an obstacle. Or, in the right hands, a breakthrough. From $11 million to $100 million in annual sales, then sold to a public company for $300 million. You donít have to be a brain surgeon to do the math.